The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection

KARAYALÇIN, Selim; Sarioglu, Mustafa; YURDAYDIN, Cihan; BOZKAYA, Hakan; TÜRKAY, Cansel; BOZDAYI, A. Mithat; Çetinkaya, Hülya; ASLAN, Nuray; UZUNALİMOĞLU, Özden

The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection

Nuray ASLAN, (Ankara Üniversitesi, Tıp Fakültesi, Hepatoloji Anabilim Dalı, Ankara, Türkiye)

A. Mithat BOZDAYI, (Ankara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Ankara, Türkiye)

Hülya ÇETİNKAYA, (Ankara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Ankara, Türkiye)

Mustafa SARIOĞLU, (Ankara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Ankara, Türkiye)

Cansel TÜRKAY, (Ankara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Ankara, Türkiye)

Hakan BOZKAYA, (Ankara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Ankara, Türkiye)

Selim KARAYALÇIN, (Ankara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Ankara, Türkiye)

Cihan YURDAYDIN, (Ankara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Ankara, Türkiye)

Özden UZUNALİMOĞLU (Ankara Üniversitesi, Tıp Fakültesi, Hepatoloji Anabilim Dalı, Ankara, Türkiye)

Turkish Journal of Gastroenterology

4 0

Yıl: 2004 Cilt: 15 Sayı: 1 Sayfa Aralığı: 21 - 26 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection

Öz:

HCV-NS5A geni (2209-2248 nt) üzerindeki aa değişimleri ile interferon tedavisine yanıt arasında bir ilişki olduğu rapor edilmiştir. Bu çalışmamızın amacı HCV genotip 1b ile enfekte Türk hastalarının IFN tedavisine verdikleri yanıtla ISDR bölgesindeki aa değişimleri arasında bir ilişki olup olmadığını incelemektedir. Yöntem: Çalışma grubumuzda 6 ay boyunca 3x3-5 MIU interferon $alpha$ 2b tedavisi alan 39 kronik C hastası (35:1b, 4:1a) bulunmaktadır. Tedavi öncesi serum örneklerinden yapılan PZR amplifikasyonları sonrası sekanslar gerçekleştirildi. Mutant tiplerde 4 aa’dan faza mutasyonlar tespit edilirken, orta tiplerde 1-3 aa mutasyon bulunmaktadır. Yaban tipte ise hiçbir aa değişimi yoktur. HCV-RNA serum virüs düzeyleri bDNA yöntemi ile analiz edildi. Bulgular: Onsekiz hasta tedaviye yanıt verirken (%46), 21 hastada yanıt alınamamıştır(%54). Aminoasit değişimleri bu iki hasta grubunda önemli bir farklılık göstermemiştir. İki grupta da orta ve yaban tip mutasyon türleri gözlenmiştir. Sonuç: Bu çalışmada IFN’a cevap ile NS5A2209-2248 bögesindeki aa değişimleri arasında bir ilişki bulunamamıştır. Hastaların büyük bir kısmında aa dizileri korunmuşluk göstermektedir.

Anahtar Kelime: Hepacivirus Mutasyon İnterferon-alfa Türkiye Genler

Konular: Cerrahi

Hepatit C genotip 1b ile Türk hastaların interferon tedavisine verdiği cevap NS5A geninin ISDR bölgesindeki mutasyonlarla ilişkili değildir

Öz:

A significant association between variations in amino acid sequences resides between 2209-2248 nucleotides of HCV non-structural 5A (NS5A) gene, and response to interferon treatment has been proposed. The aim of this study was to determine whether the amino acid sequence changes in ISDR could be correlated to response to alpha interferon treatment in Turkish patients infected with HCV genotypes 1b and 1a. Methods: Thirty-nine patients with chronic C virus infection (35 and 4 patients with genotype 1b and 1a, respectively), receiving 3x3-5 MU of interferon $alpha$-2b for six months were included in the study. Following PCR amplification of the region from pre-treatment serum samples, the products were directly sequenced. The amino acid sequence of NS5A was compared with the published sequence for HCV-J (AA 2209-2248). Mutant type was defined as three or more amino acid mutations, and intermediate type as 1-3 amino acids in this region. Otherwise, they were defined as the wild type (no amino acid mutations). HCV RNA serum viremia levels were analyzed by branched DNA assay. Results: Eighteen patients were responders (R; 46%), whereas 21 patients were non-responders (NR; 54%). Amino acid changes in both R and NR groups did not show significant difference. Intermediate or wild type strains were detected in both groups. Conclusions: In this study, we could not determine a significant association between number of amino acid changes in NS5A2209-2248 and response to interferon treatment. In the majority of the patients, it seems that amino acid sequences in this region are well conserved.

Anahtar Kelime: Turkey Genes Hepacivirus Mutation Interferon-alpha

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Dienstang JL. Non-A, non-B hepatitis. I. Recognition, epi demiology and clinical features. Gastroenterology 1983; 85: 439-62. 2. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Therapy Group. N Engl J Med 1989; 321: 1501-6. 3. Di Bisceqlie AM, Martin P, Kassianides C, et al. Recombi nant interferon alfa therapy for chronic hepatitis C. A ran domized, double blind, placebo-controlled trial. N Eng J Med 1989; 321: 1506-10. 4. Chemello L, Cavalletto L, Donada C, et al. Efficacy of a se cond cycle of interferon therapy in patients with chronic he patitis C. Gastroenterology 1997; 113: 1654-9. 5. Brower JT, Nevens F, Kleter G, et al. Efficacy of interferon dose and factors predictive of sustained response in chronic hepatitis C: final results of a Benelux multicenter study in 350 patients (Abstract). J Hepatol 1995; SI: 85.
6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 we eks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Inter national Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 31: 1426-32. 7. Camps J, Crisostomo S, Garcia-Granero M, et al. Predicti on of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714-7. 8. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3. 9. Lam NP, De Guzman LJ, Pitrak D, Layden TJ. Clinical and histologic predictors of response to interferon-alfa in patients with chronic hepatitis C viral infection. Dig Dis Sci 1994; 39: 2660-4. 10. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full length sequences of interferon-sensitive and resistant he patitis C virus I b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-30. 11. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection. N Engl J Med 1996; 334: 77-81. 12. Sen GC, Ransohoff RM. Interferon induced antiviral acti ons and their regulation. Adv Virus Res 1993; 42: 57-102. 13. Hershey JWB. Translational control in mammalian cells. Anu Rev Biochem 1991; 60: 717-55. 14. Merrick WC, Hershey JWB. Translational Control. In: Hershey J, Matheus M, Sonenberg N, eds. New York: Cold Spring Harbor Laboratory Press, 1996; 31-70. 15. Gale MJ, Korth MJ, Tang NM, et al. Evidence that hepati tis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-77. 16. Gale MJ, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-18. 17. Kurosaki M, Enomoto N, Murakami T, et al. Analysis of ge notypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to in- terferon-beta therapy. Hepatology 1997; 25: 750-3. 18. Chayama K, Tsubota A, Kobayashi M, et al. Pretreatment virus load and multiple amino acid substitutions in the in terferon sensitivity-determining region predict the outco me of interferon treatment in patients with chronic genoty pe lb hepatitis C virus infection. Hepatology 1997; 25: 745- 9. 19. Sakuma I, Enomoto N, Kurosaki M, et al. Differential ef fect of interferon on hepatitis C virus lb quasispecies on the nonstructural protein 5A gene. J Infect Dis 1999; 180: 1001-9. 20. Zeuzem S, Lee JH, Roth KW, et al. Mutations in the nonst ructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997; 25: 740-4. 21. Squadrito G, Leone F, Sartori M, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 1997; 113: 567-72. 22. Khorsi H, Castelain S, Wyseur A, et al. Mutations of hepa titis C virus lb NS5A2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997; 27:72-7.
23. Ibbarrola N, Morena-Monteaguda JA, Jaiz M, et al. Res ponse to retreatment with interferon-alpha plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence. Am J Gastroenterol 1999; 9: 2487-95. 24. Hofgartner WT, Polyak SJ, Sullivan DG, et al. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype la or lb. J Med Virol 1997; 53: 118-26. 25. Herion D, Hoofnagle JH. The interferon sensitivity-deter mining region: all hepatitis C virus isolates are not the sa me. Hepatology 1997; 25: 769-71. 26. Chomczynski P, Sacchi N. Single step method of RNA iso lation by acid-guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9. 27. Chan SW, McOmish F, Holmes EC, et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992; 73: 1131-41. 28. Squadrito G, Raffa G, Restuccia T, et al. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for pre dicting long-lasting response to interferon therapy in pati ents with HCV lb chronic hepatitis Viral Hepat 2002; 9(5): 360-9. 29. Murphy MD, Rosen HR, Marousek GI, et al. Analysis of se quence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction inter feron-alpha and ribavirin therapy in chronic hepatitis C in fection. J Hepatol 1999; 30(6): 1195-205. 30. Sarrazin C, Herrmann E, Bruch K, et al. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol 2002; 76(21): 11079-90. 31. Duverlie G, Khorsi H, Castelain S, et al. Sequence analysis of the NS5A protein of European hepatitis C virus lb isola tes and relation to interferon sensitivity. J Gen Virol 1998; 79(Pt6): 11079-81. 32. Witherell GW, Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C vi rus and interferon response. J Med Virol 2001; 63: 8-16. 33. Watanabe H, Enomoto N, Nagayama K, et al. Number and position of mutations in the interferon (IFN) sensitivity de termining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype lb infection. J Infect Dis 2001; 183(8): 1195-203.

APA	ASLAN N, BOZDAYI A, Çetinkaya H, Sarioglu M, TÜRKAY C, BOZKAYA H, KARAYALÇIN S, YURDAYDIN C, UZUNALİMOĞLU Ö (2004). The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. , 21 - 26.
Chicago	ASLAN Nuray,BOZDAYI A. Mithat,Çetinkaya Hülya,Sarioglu Mustafa,TÜRKAY Cansel,BOZKAYA Hakan,KARAYALÇIN Selim,YURDAYDIN Cihan,UZUNALİMOĞLU Özden The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. (2004): 21 - 26.
MLA	ASLAN Nuray,BOZDAYI A. Mithat,Çetinkaya Hülya,Sarioglu Mustafa,TÜRKAY Cansel,BOZKAYA Hakan,KARAYALÇIN Selim,YURDAYDIN Cihan,UZUNALİMOĞLU Özden The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. , 2004, ss.21 - 26.
AMA	ASLAN N,BOZDAYI A,Çetinkaya H,Sarioglu M,TÜRKAY C,BOZKAYA H,KARAYALÇIN S,YURDAYDIN C,UZUNALİMOĞLU Ö The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. . 2004; 21 - 26.
Vancouver	ASLAN N,BOZDAYI A,Çetinkaya H,Sarioglu M,TÜRKAY C,BOZKAYA H,KARAYALÇIN S,YURDAYDIN C,UZUNALİMOĞLU Ö The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. . 2004; 21 - 26.
IEEE	ASLAN N,BOZDAYI A,Çetinkaya H,Sarioglu M,TÜRKAY C,BOZKAYA H,KARAYALÇIN S,YURDAYDIN C,UZUNALİMOĞLU Ö "The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection." , ss.21 - 26, 2004.
ISNAD	ASLAN, Nuray vd. "The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection". (2004), 21-26.

APA	ASLAN N, BOZDAYI A, Çetinkaya H, Sarioglu M, TÜRKAY C, BOZKAYA H, KARAYALÇIN S, YURDAYDIN C, UZUNALİMOĞLU Ö (2004). The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. Turkish Journal of Gastroenterology, 15(1), 21 - 26.
Chicago	ASLAN Nuray,BOZDAYI A. Mithat,Çetinkaya Hülya,Sarioglu Mustafa,TÜRKAY Cansel,BOZKAYA Hakan,KARAYALÇIN Selim,YURDAYDIN Cihan,UZUNALİMOĞLU Özden The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. Turkish Journal of Gastroenterology 15, no.1 (2004): 21 - 26.
MLA	ASLAN Nuray,BOZDAYI A. Mithat,Çetinkaya Hülya,Sarioglu Mustafa,TÜRKAY Cansel,BOZKAYA Hakan,KARAYALÇIN Selim,YURDAYDIN Cihan,UZUNALİMOĞLU Özden The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. Turkish Journal of Gastroenterology, vol.15, no.1, 2004, ss.21 - 26.
AMA	ASLAN N,BOZDAYI A,Çetinkaya H,Sarioglu M,TÜRKAY C,BOZKAYA H,KARAYALÇIN S,YURDAYDIN C,UZUNALİMOĞLU Ö The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. Turkish Journal of Gastroenterology. 2004; 15(1): 21 - 26.
Vancouver	ASLAN N,BOZDAYI A,Çetinkaya H,Sarioglu M,TÜRKAY C,BOZKAYA H,KARAYALÇIN S,YURDAYDIN C,UZUNALİMOĞLU Ö The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. Turkish Journal of Gastroenterology. 2004; 15(1): 21 - 26.
IEEE	ASLAN N,BOZDAYI A,Çetinkaya H,Sarioglu M,TÜRKAY C,BOZKAYA H,KARAYALÇIN S,YURDAYDIN C,UZUNALİMOĞLU Ö "The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection." Turkish Journal of Gastroenterology, 15, ss.21 - 26, 2004.
ISNAD	ASLAN, Nuray vd. "The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection". Turkish Journal of Gastroenterology 15/1 (2004), 21-26.